

Preliminary Study of a New Extracorporeal Membrane Oxygenator Development When Using Pulsatile Flow

Sa Ram Lee^{1,2,4,5}, Kyung soo Lee^{1,2,4,5}, Jae Hoon Jung^{1,2,4,5}, Cho Hay Mun^{1,2,4,5}, Byoung Goo Min^{1,2,3,4}

¹Interdisciplinary Program in Medical and Biological Engineering Major, Seoul National University

²Department of Biomedical Engineering, College of Medicine, Seoul National University

³Institute of Medical and Biological Engineering, Medical Research Center, Seoul National University

⁴Korea Artificial Organ Center

⁵Cancer Research Institute, Seoul National University, Seoul, Korea

(Received December 18, 2006. Accepted March 8, 2007)

Abstract

An oxygenator is a very important artificial organ and widely used for patients with lung failure or during open heart surgery. Although an oxygenator has been widely studied worldwide to enhance its efficiency, studies on oxygenators, in particular when using a pulsatile blood flow, are domestically limited. Therefore, a new oxygenator was developed in the lab and animal experimental results are described in the paper. The oxygenator is composed of polycarbonate housing and polypropylene hollow fibers. It has a total length of 400 mm and a surface area of 1.7 m². The animal experiment lasted for 4 hours. The blood flow rate was set to 2 L/min and a pulsatile blood pump, T-PLS (Twin-Pulse Life Support), was used. Samples were drawn at the oxygenator's inlet and outlet. The total hemoglobin (Hb), saturation oxygen (sO₂), and partial oxygen pressure (pO₂), partial CO₂ pressure (pCO₂), and plasma bicarbonate ion concentration (HCO₃⁻) were measured. The oxygen and carbon dioxide transfer rates were also calculated based on the experimental data in order to estimate the oxygenator's gas transfer efficiency. The oxygen and carbon dioxide transfer rates were 16.4±1.58 and 165.7±10.96 mL/min, respectively. The results showed a higher carbon dioxide transfer rate was achieved with the oxygenator. Also, the mean inlet and outlet blood pressures were 162.79 and 137.92 mmHg, respectively. The oxygenator has a low pressure drop between its inlet and outlet. The aim of own preliminary study was to make a new oxygenator and review its performance when applying a pulsatile blood pump thus, confirming the possibility of a new oxygenator suitable for pulsatile flow.

Key words : oxygenator, pulsatile blood flow, non-pulsatile blood flow, T-PLS, ECLS, CPB

1. INTRODUCTION

An oxygenator can perform the function of the human lungs and it is a very important artificial organ in an extracorporeal life support (ECLS) circuit, e.g., cardiopulmonary bypass (CPB), extracorporeal lung assists (ECLA) and extracorporeal membrane oxygenation (ECMO) [1,2]. Oxygen diffuses along a concentration gradient across membranes into the blood flowing through the device and carbon dioxide delivered in the venous blood diffuses along a concentration gradient through the membrane into the gas. In addition, the gas transfer varies in accordance to

the total surface area, gas concentration gradients and membrane permeability [3].

The oxygenator was first conceptualized by the English scientist, Robert Hooke and developed as an extracorporeal oxygenator by French and German experimental physiologists in the 19th century. Most of the oxygenators used until the late 1970s were derived from von Schroder's bubble oxygenator and Fry and Gruber's film oxygenator. In the bubble and film oxygenators, 'direct contact' means there is no intervening barrier between the blood and gas compartments and this can cause blood trauma. Therefore, membrane oxygenators adopted a gas-permeable interface between the blood and oxygen. Since the gas does not have any direct contact with the blood in the current membrane oxygenator, blood trauma was decreased and extracorporeal oxygenators have been used for long-term applications, such as in intensive therapy of respiratory distress syndrome. Therefore, the membrane oxygenator has recently

Corresponding Author : Byoung Goo Min, Ph.D.
Department of Biomedical Engineering, College of Medicine, Seoul National University 28 Yungun-dong, Chongno-gu, Seoul, 110-744, KOREA
Tel : 02) 2072 - 3126 / Fax : 02) 2072 - 7870
E-mail : bgmin@snu.ac.kr

become the preferred clinical choice [3,4].

Many materials, such as polypropylene, polyolefin, silicone, polymethylpentene, etc., have been used in membrane oxygenators [5-7]. Also, the membrane was coated with heparin to improve the oxygenator's biocompatibility [2,8]. More recently, a study was conducted in regard to the new conceptual oxygenator, the intra-oxygenator. It was conceived to be inserted through the femoral or jugular vein and lodged in the vena cava during gas exchange. In addition, this intra-oxygenator has a smaller blood contact surface than extracorporeal oxygenators. It also reduces the infection risk and surgical operation time, while requiring a nearly zero priming volume. No blood tubes and heat exchangers are required in this system [9,10]. In addition, some researchers introduced a compliance chamber to minimize oxygenator impedance [11], implantable oxygenator [12,13] or a pump-less circuit in the extracorporeal oxygenation systems [5,14].

A new oxygenator was developed in our group and its performance when applying a pulsatile blood pump was inspected in the present study therefore, confirming the possibility of new oxygenator development, which is suitable for pulsatile flow.

II. MATERIALS AND METHODS

A. Oxygenator

The experimental oxygenator was composed of polycarbonate housing and hollow polypropylene fiber membranes. The housing length, internal and external diameters were 260, 45, and 56 mm, respectively. In addition, the inner diameter of hollow fibers was 0.240 mm and the thickness was approximately 35 μm . The hollow fiber bundle was assembled with the housing through




Fig. 1. Side View of the Experimental Oxygenator: Arrows indicate the direction of oxygen and blood flow through the device, respectively. Oxygen runs through the inside of the fibers and blood runs around the outside of the hollow fibers in the oxygenator.

Table 1. Average Blood Gas Analysis of the Samples

Hb, hemoglobin sO₂, oxygen saturation; pO₂, partial oxygen pressure pCO₂, partial carbon dioxide pressure HCO₃⁻, plasma bicarbonate ion concentration.

	Hb (g/dl)	sO ₂ (%)	pO ₂ (mmHg)	pCO ₂ (mmHg)	HCO ₃ (mmol/L)
INLET	10.6 ±0.88	49.17 ±13.30	39.6 ±10.60	44.03 ±7.81	14.73 ±2.72
OUTLET	10.47 ±0.96	105.3 ±1.41	148.63 ±31.33	26.9 ±4.24	11.54 ±2.97

a potting process by using a polyurethane adhesive agent. The potting was conducted at 1000 rpm for 30 minutes, which was followed by a trimming procedure. Finally, the caps were assembled on the potted oxygenator body, which has a total length of 400 mm and a surface area of 1.7 m². Oxygen runs through the inside of the fibers and blood runs around the outside of the hollow fibers in the oxygenator (Figure 1).

B. Animal Experiment

A canine (weighting approximately 35 kg) was used as a septic shock model by infusing LPS (lipopolysaccharide) which was diluted in 100 ml of normal saline. The femoral vein and the femoral artery were dissected for cannulation and 15 and 17 Fr catheters were inserted. Before the animal experiment, normal saline with heparin (50,000 IU/L) was circulated through the entire system for anticoagulation. The animal was heparinized, with 250 units/kg for the initial anticoagulation, and infused with heparin at 30 ml/h during the experiment. Ketamin 5 cc and Xylazine 1.8 cc were used as anesthesia and it was maintained by inhalation of N₂O gas and Enflurane. The animal experiment lasted for 4 hours and blood was circulated at a flow rate of 2 L/min. During the animal experiments, pressures were monitored at the oxygenator inlet and outlet. Ten milliliters of blood was drawn




Fig. 2. Schematic Illustration of the In Vivo Experiment Circuit : QB, blood flow rate; Blood pump, T-PLS (pulsatile blood pump).

upstream and downstream of the oxygenator. Samples were analyzed by using automatic blood gas analysis (ABL520, Radiometer Limited, UK) for total hemoglobin (Hb), saturation oxygen (sO₂), partial oxygen pressure (pO₂), partial carbon dioxide pressure (pCO₂), and plasma bicarbonate ion concentration (HCO₃⁻). Moreover, oxygen transfer rates and carbon dioxide transfer rates were calculated. The scheme for the animal experiment is shown in Figure 2.

C. Blood Pump

The T-PLS (Twin-pulse life support, NewHeartBio, Korea) was used as a blood pump in the present study (Figure 3). It consists of an electrical power supply, a control panel, an actuator and two blood sacs. The reciprocating actuator alternatively squeezes on the left and right blood sacs. When the actuator squeezes the left sac, the blood in the sac can move only in a forward direction because of polymer check-valves, which prevent blood from flowing backward; at the same time, the right sac expands and blood fills it. In the same manner, blood in the right sac moves forward when the actuator squeezes that sac and in this alternate fashion the actuator creates a pulsatile flow. The advantages include an easily adjustable pump rate, an auto-priming mode, a suction detection mode, an alarm and flow estimation. This device is used in a lot of research and in many experiments for pulse flow [15]. Furthermore, it received manufacturing approval from the Korea Food and Drug Administration in 2004 and has been used in clinics.




Fig. 3. Pulsatile Blood Pump, T-PLS (NewHeartBio, Korea) : The pulsatile blood pump is composed of blood sacs, an electrical power supply, a control panel, actuator, and polymer check-valve in each sac.

D. Equations

The gas transfer rate was calculated as follow:

- Oxygen content (Vol %)
= (Hb×1.34×%O₂saturation)/ 100 + pO₂×0.003
- Oxygen transfer rate (ml/min)
= QB x (Arterial O₂ content - Venous O₂ content)
- Total carbon dioxide (mmol/L)
= HCO₃⁻ + 0.03×pCO₂
- Carbon dioxide transfer rate (ml/min)
= 22.4× (Venous tCO₂ - Arterial tCO₂) ×QB

Hb: hemoglobin (g/dl), pO₂: partial O₂ pressure (mmHg), pCO₂: partial carbon dioxide pressure (mmHg), QB: blood flow rate (L/min), HCO₃⁻: plasma bicarbonate ion concentration (mmol/L)

All data are presented as mean ± standard deviation.

III. RESULTS

During the experiments, there were no technical problems concerning the new oxygenator. In addition, no plasma leakage or membrane rupture was observed and the animal was well sustained in all circulation sessions. The results for blood gas analysis are provided in Table 1. Hemoglobin (Hb) levels were found not to be significantly different between the oxygenator inlet and outlet. After the blood was run through the oxygenator, the mean oxygen saturation level was sufficiently maintained. The inlet pO₂ indicated the blood was deoxygenated but the increase in pO₂ through the oxygenator indicates the blood was adequately oxygenated. A similar trend was observed for the pCO₂ levels upstream and downstream of the oxygenator. The inlet and outlet oxygen contents were 7.01±1.83 and 15.21±1.28% respectively. Likewise, the inlet and outlet total carbon dioxide were 16.04±2.46 and 12.36±2.92 mmol/L, respectively. The results of the HCO₃⁻ used were used to calculate the total carbon dioxide. The average O₂ and CO₂ transfer rates were shown in Table 2. Also, the oxygenator has a low pressure drop between the oxygenator inlet and outlet. The mean inlet and outlet blood pressures were 162.79 and 137.92 mmHg, respectively and thus the pressure drop across the oxygenator was approximately 24.87 mmHg. The representative inlet and outlet pressure profiles are show in Figure 4.

Table 2. Average O₂ and CO₂ Transfer Rate of the Device

	O ₂	CO ₂
Gas transfer rate (mL/min)	16.4 ± 1.58	165.7 ± 10.96




Fig. 4. Representative Device Inlet and Outlet Pressure versus Time : The mean inlet and outlet pressures are 162.79 and 137.92 mmHg respective.

IV. DISCUSSION

During the last decades, previous studies on pulsatile perfusion revealed the advantageous effects of blood pulsation during ECLS circuits [16]. When the pulsatile flow was used in CPB, microcirculation into end organs was improved. Besides, metabolism in vital organs, such as, the brain, heart, liver, kidney and pancreas, was also enhanced. The pulsatile flow was reported to have a positive influence on reducing edema formation, systemic inflammatory response syndrome and postoperative death, as compared with CPB with non-pulsatile blood flow [17-20]. Pulsatile perfusion is also suggested in an ECMO or a VAD support, because it can produce more physiologic hemodynamics [21]. Recently, the pulsatile perfusion was successfully applied in clinic practice [22].

Although the advantageous effects of pulsatile flow on blood perfusion have been widely discussed, most of the conventional ECLS circuits are adopting roller and centrifugal blood pumps. This may be caused by larger blood damage with a pulsatile blood pump [19]. A previous study also compared the oxygen transfer rate under the steady flow with that of pulsatile blood flow, when using a commercial oxygenator which contained an air chamber to reduced blood cell trauma. Their results revealed the average oxygen transfer rate was reduced by 10% with pulsatile blood flow [23]. In addition, the structural designs of current hollow fiber membrane oxygenators may also have a direct impact on the pulsatility. Therefore, when the pulsatile flow is applied in the ECLS circuit, the oxygenator which is optimized more for pulsatile blood flow is required for less blood trauma and high

gas transfer efficiency. Thus, the present study was performed by using the pulsatile blood flow to verify the oxygenator efficiency.

The O₂ transfer rate with the oxygenator in the present study was relatively low, when compared with other commercial oxygenators [14]. This might be caused by the low blood flow rates and high venous blood O₂ content. However, the CO₂ transfer rates are promisingly high and thus the oxygenator may be useful for arteriovenous CO₂ removal (AVCO₂R) treatment for patients with end stage chronic obstructive pulmonary disease (COPD). In addition, the blood pressure drop across the oxygenator was less than 24.87 mmHg, which is lower than that in other commercial oxygenators [6,24]. Unlike a commercially available oxygenator, which has a complex blood flow pathway, the experimental oxygenator is characterized by a simple blood path because the blood pathway in the oxygenator is straight. A low pressure drop between the oxygenator inlet and outlet is assumed to result from this simple blood pathway. In addition, a simple blood pathway is believed to enhance hemolytic characteristics with the oxygenator. The oxygenator presented in this study is still an experimental prototype and further optimizations are required in order to increase the oxygen transfer rate and to improve biocompatibility. However, the new oxygenator is assumed to be not only less blood traumatic but also more suitable for pulsatile flow.

This animal study was conducted with a focus on the gas transfer ability of the experimental oxygenator. The results obtained in the present study revealed adequate gas transfer efficiency with the oxygenator, in particular, a high CO₂ transfer rate. Moreover, the experimental oxygenator is a useful trial to develop a new oxygenator which has the improved gas transfer efficiency of gas transfer and reduction in blood hemolysis, when using a pulsatile blood pump.

REFERENCE

- [1] R. Bensberg, R. Dembinski, R. Kopp, R. Kuhlen, "Artificial lung and extracorporeal gas exchange," *Panminerva Medica*, vol.47, pp.11-17, 2005.
- [2] F. Mielck, M. Quintel, "Extracorporeal membrane oxygenation," *Current Opinion in Critical Care*, vol.11, pp.87-93, 2005.
- [3] H. Iwahashi, K. Yuri, Y. Nose, "Development of the oxygenator: past, present, and future," *Journal of Artificial Organs*, vol.7, pp.111-120, 2004.
- [4] M. W. Lim, "The history of extracorporeal oxygenators," *Anaesthesia*, vol.61, pp.984-995, 2006.
- [5] K. Tamesue, S. Ichiba, S. Nawa, N. Shimizu, "An experimental study on pumpless extracorporeal membrane oxygenation (ECMO) support in a canine model," *Acta Medica Okayama*,

- vol.60, pp.167-172, 2006.
- [6] X. M. Mueller, H. T. Tevæarai, M. Augstburger, J. Horisberger, L. K. von Segesser, "Experimental evaluation of the Dideco D903 Avant 1.7 hollow-fibre membrane oxygenator," *Perfusion*, vol.13, pp.353-359, 1998.
- [7] E. Khoshbin, C. Westrope, S. Pooboni, D. Machin, H. Killer, G. J. Peck, A. W. Sosnowski, R. K. Firmin, "Performance of polymethyl pentene oxygenators for neonatal extracorporeal membrane oxygenation: a comparison with silicone membrane oxygenators," *Perfusion*, vol.20, pp.129-134, 2005.
- [8] M. D. Veysel Kutay, M. D. Tevfik Noyan, M. D. Sedat Ozcan, M. D. Yasin Melek, M. D. Hasan Ekim, M. D. Cevat Yakut, "Biocompatibility of heparin-coated cardiopulmonary bypass circuits in coronary patients with left ventricular dysfunction is superior to PMEA-coated circuits," *J. CARD. SURG.*, vol.21, pp.572-577, 2006.
- [9] G. F. Cattaneo, H. Reul, T. Schmitz-Rode, U. Steinseifer, "Intravascular blood oxygenation using hollow fibers in a disk-shaped configuration: experimental evaluation of the relationship between porosity and performance," *ASAIO Journal*, vol.52, pp.180-185, 2006.
- [10] G. Cattaneo, A. Strauss, H. Reul, "Compact intra- and extracorporeal oxygenator developments," *Perfusion*, vol.19, pp.251-255, 2004.
- [11] K. E. Cook, C. E. Perlman, R. Seipelt, C. L. Backer, C. Mavroudis, L. F. Mockros, "Hemodynamic and gas transfer properties of a compliant thoracic artificial lung," *ASAIO Journal*, vol.51, pp.404-411, 2005.
- [12] J. B. Zwischenberger, C. M. Anderson, K. E. Cook, S. D. Lick, L. F. Mockros, R. H. Bartlett, "Development of an implantable artificial lung: challenges and progress," *ASAIO Journal*, vol.47, pp.316-320, 2001.
- [13] H. Sato, I. Taga, "In vitro evaluation of a newly developed implantable artificial lung," *Acta Med Okayama*, vol.60, pp.113-119, 2006.
- [14] D. Jegger, J. P. Revely, J. Horisberger, I. Mallabiabarrena, I. Seigneul, M. Jachertz, L. K. Von Segesser, "Ex vivo evaluation of a new extracorporeal lung assist device: NovaLung membrane oxygenator," *International Journal of Artificial Organs*, vol.28, pp.985-999, 2005.
- [15] K. Lee, J. H. Jeong, C. H. Mun, J. C. Lee, B. G. Min, "The Effect of Pulsatile Flow on Ultrafiltration In-Vitro Study and Comparison with Roller Pump," *J. Biomed. Eng. Res.*, vol.26, pp.337-341, 2005.
- [16] A. Undar, "Pulsatile versus nonpulsatile cardiopulmonary bypass procedures in neonates and infants: from bench to clinical practice," *ASAIO Journal*, vol.51, pp.vi-x, 2005.
- [17] B. Ji, A. Undar, "An evaluation of the benefits of pulsatile versus nonpulsatile perfusion during cardiopulmonary bypass procedures in pediatric and adult cardiac patients," *ASAIO Journal*, vol.52, pp.357-361, 2006.
- [18] C. H. Lim, H. S. Son, "Comparison of coronary artery blood flow and hemodynamic energy in a pulsatile pump versus a combined nonpulsatile pump and an intra-aortic balloon pump," *ASAIO Journal*, vol.52, pp.595-597, 2006.
- [19] H. K. Kim, H. S. Son, Y. H. Fang, S. Y. Park, C. M. Hwang, K. Sun, "The effects of pulsatile flow upon renal tissue perfusion during cardiopulmonary bypass: a comparative study of pulsatile and nonpulsatile flow," *ASAIO Journal*, vol.51, pp.30-36, 2005.
- [20] G. Pennati, G. B. Fiore, F. Inzoli, F. Mastrantonio, D. Galavotti, M. Fini, "Mass transfer efficiency of a commercial hollow fibre oxygenator during six-hour in vitro perfusion with steady and pulsatile blood flow," *International Journal of Artificial Organs*, vol.21, pp.97-106, 1998.
- [21] S. Agati, G. Ciccarello, "Pulsatile ECMO and VAD: a dual use of a new device in pediatric cardiac patients," *ASAIO Journal*, vol.52, pp.501-504, 2006.
- [22] S. Agati, C. Mignosa, G. Ciccarello, S. Dario, A. Undar, "Pulsatile ECMO in neonates and infants: first European clinical experience with a new device," *ASAIO Journal*, vol.51, pp.508-512, 2005.
- [23] F. Boschetti, K. E. Cook, C. E. Perlman, L. F. Mockros, "Blood flow pulsatility effects upon oxygen transfer in artificial lungs," *ASAIO Journal*, vol.49, pp.678-686, 2003.
- [24] S. Horton, C. Thuys, M. Bennett, S. Augustin, M. Rosenberg, C. Brizard, "Experience with the Jostra Rotaflo and Quadrox oxygenator for ECMO," *Perfusion*, vol.19, pp.17-23, 2004.